Evaluating the benefits and risks of puberty blockers and gender‐affirming hormones for transgender adolescents

Documenti analoghi

• Fertility outcomes in male adults with congenital hypogonadotropic hypogonadism treated during puberty with human chorionic gonadotropin and recombinant follicle stimulating hormone
  di: Francisca Grob, et al.
  Pubblicazione: (2024)
• The Brexit in adolescent gender dysphoria care?
  di: Ludovica Barbi, et al.
  Pubblicazione: (2024)
• Osteocalcin: A potential marker to identify and monitor girls with rapidly progressive central precocious puberty
  di: Wei Qin, et al.
  Pubblicazione: (2024)
• Ravulizumab facilitates reduced burden of vascular access, a major benefit in paediatric atypical haemolytic uraemic syndrome
  di: Freya Bleathman, et al.
  Pubblicazione: (2024)
• Characteristics of children and adolescents with recurrent mental health emergency visits and clinicians' intervention tendencies
  di: Oguz Bilal Karakus, et al.
  Pubblicazione: (2024)